NCT05508178 - Recombinant, Bivalent, Norovirus Vaccine Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions

Norovirus

Interventions

BIOLOGICAL

Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)

Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant

BIOLOGICAL

Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)

Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant

DRUG

Placebo

Norovirus vaccine (rNV-2v) vehicle without antigen

Trial Locations (1)

Center for Vaccinology (CEVAC), Ghent University and University Hospital, Ghent